Platelet function analyser (PFA‐100) results and von Willebrand factor deficiency: a 16‐year ‘real‐world’ experience
Authors:
- 10 March 2015
- journal article
- Published by Wiley in Haemophilia
- Vol. 21 (5) , 646-652
Abstract
Summary: The platelet function analyser (PFA‐100) is a biological tool designed to explore primary haemostasis. This system has thus been widely demonstrated as reliable in detecting von Willebrand factor (VWF) deficiency. However, most studies were based on patients benefitting from regular medical care and accurate diagnosis, and it would seem probable that the results were somewhat optimistic, and do not reflect its performances in ‘real‐world’ situations. We have chosen to study the reliability of PFA‐100 for screening VWF ristocetin cofactor (VWF:RCo) deficiency. We retrospectively analysed the results (n = 6431) of 4027 patients referred to our centre between October 1997 and June 2013 and in whom PFA‐Epi, PFA‐ADP, and VWF:RCo activity had been evaluated. We studied the influence of blood group on the results and the performances of each method in a subgroup of 213 patients with genetically confirmed von Willebrand disease. We have shown that the PFA‐100 system, in our experience, constitutes an excellent screening test for detecting VWF:RCo deficiency, whatever the clinical situation, in ‘real‐world’ conditions. The negative predictive value (NPV), the positive predictive value, the sensitivity and the specificity were respectively: 0.98, 0.51, 0.98 and 0.40. When values adjusted for blood group are used, NPV and sensitivity are inferior to those using normal values which have not been adjusted for blood group. We have shown the PFA‐100 method to be more efficient in screening for VWF deficiency than the VWF:RCo technique.Keywords
This publication has 22 references indexed in Scilit:
- Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 UpdateSeminars in Thrombosis and Hemostasis, 2013
- Clinical Utility of the PFA-100Seminars in Thrombosis and Hemostasis, 2008
- von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)1Haemophilia, 2008
- The relationship between ABO groups and subgroups, factor VIII and von Willebrand factorHaematologica, 2007
- Diagnostic performance of the platelet function analyzer (PFA-100®) for the detection of disorders of primary haemostasis in patients with a bleeding history–a systematic review and meta-analysisPlatelets, 2007
- Influence of ABO blood groups on primary hemostasisTransfusion, 2001
- Influence of the ABO Blood Type on the Platelet Function Analyzer PFA-100Thrombosis and Haemostasis, 2001
- Impact, Diagnosis and Treatment of von Willebrand DiseaseThrombosis and Haemostasis, 2000
- Performance characteristics and clinical evaluation of an in vitro bleeding time device — Thrombostat 4000Thrombosis Research, 1995
- The effect of ABO blood group on the diagnosis of von Willebrand diseaseBlood, 1987